A Massachusetts federal judge running the first bellwether in multidistrict litigation over whether GlaxoSmithKline's anti-nausea medication Zofran causes birth defects said Wednesday that he's considering an October starting date after a lengthy postponement triggered by the coronavirus pandemic.